Vynleads (VYND) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 15, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	333-227499
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Entity Tax Identification Number	47-4584272
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	596 Herrons Ferry Road
Entity Address, Address Line Two	Suite 301
Entity Address, City or Town	Rock Hill
Entity Address, State or Province	SC
Entity Address, Postal Zip Code	29730
City Area Code	(845)
Local Phone Number	745-0981
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,599,830

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 19,436	$ 503
Holdback receivable from merchant, net of reserve for refunds of $58 and $58, respectively	15,764	15,764
Prepaid expenses and other current assets	4,071	8,061
Total current assets	39,271	24,328
Total assets	39,271	24,328
Current Liabilities:
Accounts payable and accrued expenses	269,366	290,788
Notes payable	432,461	354,029
Notes payable - related party	15,000	15,000
Total current liabilities	716,827	659,817
Total liabilities	716,827	659,817
Commitments and contingencies (See Note 6)
Stockholders' Deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares and 11,599,830 shares issued and outstanding, respectively	1,160	1,160
Additional paid-in capital	1,656,752	1,624,252
Accumulated deficit	(2,335,468)	(2,260,901)
Total stockholders' deficit	(677,556)	(635,489)
Total liabilities and stockholders' deficit	$ 39,271	$ 24,328

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,599,830
Common stock, shares outstanding	11,599,830	11,599,830

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue, net of refunds and chargebacks
Cost and Expenses:
Cost of revenue	12,922	7,328
Selling, general and administrative expenses	56,836	71,720
Total costs and expenses	69,758	79,048
Loss from operations	(69,758)	(79,048)
Interest expense	(4,809)	(3,139)
Net loss before provision for income taxes	(74,567)	(82,187)
Provision for income taxes
Net loss	$ (74,567)	$ (82,187)
Net loss per common share, basic	$ (0.01)	$ (0.01)
Net loss per common share, diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding, basic	11,599,830	11,599,830
Weighted average common shares outstanding, diluted	11,599,830	11,599,830

Condensed Statements of Stockho

Condensed Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 1,160	$ 1,494,252	$ (1,987,278)	$ (491,866)
Beginning balance, shares at Dec. 31, 2021	11,599,830
In kind contribution of services		32,500		32,500
Net loss			(82,187)	(82,187)
Ending balance, value at Mar. 31, 2022	$ 1,160	1,526,752	(2,069,465)	(541,553)
Ending balance, shares at Mar. 31, 2022	11,599,830
Beginning balance, value at Dec. 31, 2022	$ 1,160	1,624,252	(2,260,901)	$ (635,489)
Beginning balance, shares at Dec. 31, 2022				11,599,830
In kind contribution of services		32,500		$ 32,500
Net loss			(74,567)	(74,567)
Ending balance, value at Mar. 31, 2023	$ 1,160	$ 1,656,752	$ (2,335,468)	$ (677,556)
Ending balance, shares at Mar. 31, 2023	11,599,830

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (74,567)	$ (82,187)
Adjustments to reconcile net loss to net cash flows used in operating activities
In kind contribution of services	32,500	32,500
Changes in operating assets and liabilities and other, net	(19,000)	7,782
Net cash flows used in operating activities	(61,067)	(41,905)
Cash flows from financing activities:
Proceeds from notes payable	80,000	40,000
Cash overdraft		189
Net cash flows provided by financing activities	80,000	40,189
Net increase (decrease) in cash	18,933	(1,716)
Cash at beginning of period	503	1,716
Cash at end of period	19,436
Supplemental disclosure of cash flow information:
Income taxes paid
Interest paid

Business

Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who have prediabetes or type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern Our unaudited condensed financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt and equity securities, as well as borrowings from related parties. During the quarters ended March 31, 2023 and 2022, we have reported net losses of $ 74,567 and $ 82,187 677,556 and an accumulated deficit of $ 2,335,468 Despite our current sales, expense, cash flow projections, and aggregate cash and holdback 15,764 Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Accounting Principles The accompanying unaudited condensed financial statements (the “Financial Statements”) of Vynleads, Inc. (the “Company,” “we,” “us” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and, therefore, do not include all information and footnotes required by GAAP for complete financial statements. In our opinion, the Financial Statements contain all adjustments of a normal recurring nature necessary to present fairly our financial position as of March 31, 2023 and the results of our operations and cash flows for the three months and months Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements. Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value. Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $ 58 58 Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three months Percentage of Revenue by Type Three months ended March 31, (Unaudited) 2022 2021 Internet content subscriptions — — Nutritional supplements — — Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue. Advertising Costs Advertising costs for the three months ended March 31, 2023 and 2022 were $ 0 0 Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. St o ck-base compensatio i me a s e a e v u h awar an i recognize a a e xpens ove th requisite e v Accordingly th Black-Sch o e opti o pricin m o de i utilize t d e riv a estimate fai v u e The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Gr a Date Price of Common S o c h a e c o h a g a n Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of March 31, 2023 and December 31, 2022. Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $ 15,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,531 1,346 On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 100,000 0.225 On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2023 and 2022, $ 32,500 32,500 On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2020, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed until May 2023. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable On January 17, 2023, the company executed a note payable to an individual in the amount of $ 20,000 5 due date after one year of execution, or a date in the which the Company secures one million in total investment capital, whichever occurs first. 200 On October 20, 2022, the Company executed a note payable to an individual in the amount of $ 25,000 5 due date after one year of execution, or the date in the which the Company secures one million in total investment capital, whichever occurs first. 555 On August 12, 2022, the company executed a note payable to an individual in the amount of $ 20,000 5 due date after one year of execution, or the date in the which the Company secures one million in total investment capital, whichever occurs first. Accrued interest as of March 31, 2023 and December 31, 2022 is $ 252 247 On May 18, 2022, the Company executed a note payable to an individual in the amount of $ 40,000 , interest accrues at 5 % per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,737 1,233 On February 10, 2022, the Company executed a note payable to an individual in the amount of $ 20,000 , interest accrues at 5 % per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest as of March 31, 2023 and December 31, 2022 is $ 1,134 887 On January 26, 2022, the Company executed a note payable to an individual in the amount of $ 20,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest as of March 31, 2023 and December 31, 2022 is 1,175 and $ 929 On December 1, 2021, the Company executed a note payable to an individual in the amount of $ 15,000 interest accrues at 5 per annum, unsecured, and due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest as of March 31, 2023 and December 31, 2022 is $ 996 and $ 812 respectively. This note is currently in default. On September 28, 2021, the Company executed a note payable to an individual in the amount of $ 50,000 5 due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 3,760 3,143 On August 4, 2021, the Company executed a note payable to an individual in the amount of $ 15,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,241 1,056 On May 10, 2021, the Company executed a note payable to an individual in the amount of $ 20,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 1,890 1,644 On April 15, 2021, the Company executed a note payable to an individual in the amount of $ 10,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 979 856 On March 16, 2021, the Company executed a note payable to Mr. Sergei Stetsenko, a member of our Board of Directors, in the amount of $ 15,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 1,531 1,346 On December 17, 2020, the Company executed a note payable to an individual in the amount of $ 19,500 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 2,228 1,987 On October 27, 2020, the Company executed a note payable to an individual in the amount of $ 10,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 and December 31, 2022 1,212 1,089 On May 5, 2020, the Company received loan proceeds in the amount of $ 27,000 The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, 6,250 March 31, 2023 and December 31, 2022 13,484 and $ 14,529 3,433 The Company has submitted the application for forgiveness of the PPP Loan in accordance with the terms of the CARES Act and are in discussions with Bank of America (the lender). During the loan forgiveness process, repayment is temporarily deferred for borrowers until the SBA remits the final loan forgiveness amount to the lender. If granted full forgiveness, Bank of America confirmed that interest and penalties would be removed along with the principal of the loan. On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 50,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. 1,250 March 31, 2023 and December 31, 2022 7,168 6,551 On November 18, 2019, the Company executed a note payable to an individual in the amount of $ 25,000 5 due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. March 31, 2023 and December 31, 2022 4,209 3,900

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Employment Agreement On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term. Mr. Mannine’s compensation includes: · an annual base salary of $ 130,000 · an annual bonus as determined by the board of directors; · a grant of 10 100,000 0.225 · participation in all benefit plans we may offer our employees; and · 20 paid vacation days annually. Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows: · if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation); · if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid. The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses. On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2023 and March 31, 2022, $ 32,500 32,500 Commitments On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed in May 2023. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions. On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $ 45,000 ($ 0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. Under terms of the consulting agreement, we agree to pay Primoris $ 8,000 96,000 96,000 The agreement was not renewed upon expiration date. Contingencies In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non-payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

Concentration of Credit Risk an

Concentration of Credit Risk and Major Customers and Suppliers	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	7. Concentration of Credit Risk and Major Customers and Suppliers We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	8. Stockholders’ Equity Our authorized capital stock consists of 50,000,000 0.0001 5,000,000 0.0001 11,599,830 11,599,830 no In-kind Contribution of Service On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. During the three months ended March 31, 2023 and March 31, 2022, $ 32,500 32,500 Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants On October 10, 2017, we entered into the Financing Agreement with CRG. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 0.225 34,405 45 2.2 5 During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 0.225 1,670 0.225 45 2.51 5 On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 0.90 March 31, 2023 100,000 1,905 0.225 45 2.63 5 Warrants expired as of March 31,2023. As of December 31, 2022, the intrinsic value for warrants outstanding and exercisable is $ 19,288 The following table summarizes information about the warrants earned and outstanding as of March 31, 2023 and December 31, 2022: Warrants Earned and Outstanding March 31, 2023 (Unaudited) December 31, 2022 Weighted Weighted Average Average Exercise Exercise Warrants Price Warrants Price Outstanding, beginning of period 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired 485,766 — — — Outstanding, end of period — — 485,766 $ 0.364 Exercisable, end of period — — 485,766 $ 0.364 As of March 31, 2023 (Unaudited) Warrants Outstanding and Exercisable by Range of Exercise Price Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price — — — — — — As of December 31, 2022 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 1.12 $0.364 485,766 $0.364

Stock Option Plan

Stock Option Plan	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock Option Plan	9. Stock Option Plan In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000. Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferrable. Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately cancelled. In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant. The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events. On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 6 100,000 0.225 13,221 45 2.2 10 No three months ended March 31, 2023 and 2022 As of March 31, 2023 and December 31, 2022 43,500 5,000 The following table summarizes information about stock options outstanding and exercisable as of as of March 31, 2023 and December 31, 2022: Summary of Information Regarding about Stock Options Outstanding and Exercisable March 31, 2023 (Unaudited) December 31, 2022 Weighted Weighted Average Average Exercise Exercise Options Price Options Price Outstanding, beginning of period 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of period 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of period 1,000,000 1,000,000 As of March 31, 2023 (Unaudited) Options Outstanding by Exercise Price Range Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 5.68 $0.225 100,000 $0.225 As of December 31, 2021 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 5.93 $0.225 100,000 $0.225

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events No subsequent events to report.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of Accounting Estimates	Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $ 58 58
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three months Percentage of Revenue by Type Three months ended March 31, (Unaudited) 2022 2021 Internet content subscriptions — — Nutritional supplements — —
Shipping and Handling Costs	Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Advertising Costs	Advertising Costs Advertising costs for the three months ended March 31, 2023 and 2022 were $ 0 0
Loss Per Share	Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation We account for stock based instruments issued to employees and non-employees for services in accordance with Accounting Standard Codification (“ASC”) Topic 718. St o ck-base compensatio i me a s e a e v u h awar an i recognize a a e xpens ove th requisite e v Accordingly th Black-Sch o e opti o pricin m o de i utilize t d e riv a estimate fai v u e The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Gr a Date Price of Common S o c h a e c o h a g a n
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of March 31, 2023 and December 31, 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to us.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Percentage of Revenue by Type	Percentage of Revenue by Type Three months ended March 31, (Unaudited) 2022 2021 Internet content subscriptions — — Nutritional supplements — —

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Warrants Earned and Outstanding	Warrants Earned and Outstanding March 31, 2023 (Unaudited) December 31, 2022 Weighted Weighted Average Average Exercise Exercise Warrants Price Warrants Price Outstanding, beginning of period 485,766 $ 0.364 485,766 $ 0.364 Granted — — — — Exercised — — — — Forfeited — — — — Expired 485,766 — — — Outstanding, end of period — — 485,766 $ 0.364 Exercisable, end of period — — 485,766 $ 0.364
Warrants Outstanding and Exercisable by Range of Exercise Price	Warrants Outstanding and Exercisable by Range of Exercise Price Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price — — — — — — As of December 31, 2022 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 0.90 485,766 1.12 $0.364 485,766 $0.364

Stock Option Plan (Tables)

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Information Regarding about Stock Options Outstanding and Exercisable	Summary of Information Regarding about Stock Options Outstanding and Exercisable March 31, 2023 (Unaudited) December 31, 2022 Weighted Weighted Average Average Exercise Exercise Options Price Options Price Outstanding, beginning of period 100,000 $ 0.225 100,000 $ 0.225 Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, end of period 100,000 $ 0.225 100,000 $ 0.225 Exercisable, end of period 100,000 $ 0.225 100,000 $ 0.225 Options available for future grant, end of period 1,000,000 1,000,000
Options Outstanding by Exercise Price Range	Options Outstanding by Exercise Price Range Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 5.68 $0.225 100,000 $0.225 As of December 31, 2021 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $ 0.225 100,000 5.93 $0.225 100,000 $0.225

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ 74,567	$ 82,187
Working Capital Deficit	677,556
Retained Earnings (Accumulated Deficit)	2,335,468		$ 2,260,901
Holdback Receivable from merchant, net of reserve for refunds	$ 15,764		$ 15,764

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Percentage of Revenue by Type) (Details) - Revenue, Product and Service Benchmark [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Internet Content Subscriptions [Member]
Product Information [Line Items]
Concentration Risk, Percentage
Nutritional Supplements [Member]
Product Information [Line Items]
Concentration Risk, Percentage

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Refunds	$ 58		$ 58
Marketing and Advertising Expense	$ 0	$ 0
Potentially dilutive shares	585,766	585,766

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended		12 Months Ended
	Mar. 16, 2021	Jun. 14, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Options issued
Exercise price
In-kind Contribution of Service			$ 32,500	$ 32,500
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Expected term		10 years
Options issued		100,000
Exercise price		$ 0.225
In-kind Contribution of Service			32,500	$ 32,500
Note Payable [Member] | Mr Sergei Stetsenko [Member]
Related Party Transaction [Line Items]
Note payable	$ 15,000
Interest rate	5%
Term	due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest			$ 1,531		$ 1,346

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)

Jan. 17, 2023

Oct. 20, 2022

Aug. 12, 2022

May 18, 2022

Feb. 10, 2022

Jan. 26, 2022

Dec. 01, 2021

Oct. 04, 2021

Sep. 28, 2021

Sep. 15, 2021

Aug. 04, 2021

May 10, 2021

Apr. 15, 2021

Mar. 16, 2021

Dec. 17, 2020

Oct. 27, 2020

May 05, 2020

Nov. 18, 2019

Mar. 31, 2023

Dec. 31, 2022

May 14, 2020

Note Payable 11723 [Member]

Short-Term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5%

Term

due date after one year of execution, or a date in the which the Company secures one million in total investment capital, whichever occurs first.

Accrued interest

$ 200

Note Payable 102022 [Member]

Short-Term Debt [Line Items]

Note payable

$ 25,000

Interest rate

5%

Term

due date after one year of execution, or the date in the which the Company secures one million in total investment capital, whichever occurs first.

Accrued interest

$ 555

Note Payable A [Member]

Short-Term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5%

Term

due date after one year of execution, or the date in the which the Company secures one million in total investment capital, whichever occurs first.

Accrued interest

$ 252

$ 247

Note Payable 51822 [Member]

Short-Term Debt [Line Items]

Note payable

$ 40,000

Interest rate

5%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 1,233

1,737

Note Payable One [Member]

Short-Term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 887

1,134

Note Payable Two [Member]

Short-Term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,175

929

Note Payable Three [Member]

Short-Term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

996

812

Note Payable Four [Member]

Short-Term Debt [Line Items]

Note payable

$ 50,000

Interest rate

5%

Term

due after one year of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

3,760

3,143

Note Payable Five [Member]

Short-Term Debt [Line Items]

Note payable

$ 15,000

Interest rate

500%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,241

1,056

Note Payable Six [Member]

Short-Term Debt [Line Items]

Note payable

$ 20,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,890

1,644

Note Payable Seven [Member]

Short-Term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

979

856

Note Payable [Member] | Mr Sergei Stetsenko [Member]

Short-Term Debt [Line Items]

Note payable

$ 15,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,531

1,346

Note Payable Ten [Member]

Short-Term Debt [Line Items]

Note payable

$ 19,500

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

2,228

1,987

Note Payable Eleven [Member]

Short-Term Debt [Line Items]

Note payable

$ 10,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

1,212

1,089

P P P Loan [Member]

Short-Term Debt [Line Items]

Note payable

13,484

14,529

Term

The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum,

Proceeds from Loans

$ 27,000

PPP Courtesy Credit

$ 6,250

Debt Instrument, Periodic Payment

$ 3,433

Note Payable Twelve [Member]

Short-Term Debt [Line Items]

Note payable

$ 50,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

7,168

6,551

$ 1,250

Note Payable Thirteen [Member]

Short-Term Debt [Line Items]

Note payable

$ 25,000

Interest rate

5%

Term

due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Accrued interest

$ 4,209

$ 3,900

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)			3 Months Ended		12 Months Ended
	Feb. 12, 2020	Jun. 14, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Options issued
Exercise price
In-kind Contribution of Service			$ 32,500	$ 32,500
Primoris Group Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 45,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.225
Payable in advance			8,000
Accrued expense			96,000		$ 96,000
Primoris Group Inc [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Defined Benefit Plan Disclosure [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	100,000
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Annual base salary		$ 130,000
Expected life		10 years
Options issued		100,000
Exercise price		$ 0.225
In-kind Contribution of Service			$ 32,500	$ 32,500

Stockholders' Equity (Informati

Stockholders' Equity (Information About Warrants Earned and Outstanding) (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, beginning of period	485,766	485,766
Weighted average exercise price outstanding, beginning of period	$ 0.364	$ 0.364
Granted
Weighted average exercise price, Granted
Exercised
Weighted average exercise price, Exercised
Forfeited
Weighted average exercise price, Forfeited
Expired	485,766
Weighted average exercise price, Expired
Outstanding, end of period		485,766
Weighted average exercise price outstanding, end of period		$ 0.364
Exercisable, end of period		485,766
Weighted average exercise price exercisable, end of period		$ 0.364

Stockholders' Equity (Warrants

Stockholders' Equity (Warrants Outstanding by Price Range) (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of exercise price, upper limit		$ 0.90
Number outstanding		485,766
Remaining Average Contractual Life		1 year 1 month 13 days
Weighted Average Exercise Price, Outstanding		$ 0.364
Number exercisable		485,766
Weighted average exercise price, exercisable		$ 0.364
Range of exercise price, lower limit		$ 0.225

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock, shares authorized				50,000,000		50,000,000
Common stock, par value				$ 0.0001		$ 0.0001
Preferred stock, shares authorized				5,000,000		5,000,000
Preferred stock, par value				$ 0.0001		$ 0.0001
Common stock, shares issued				11,599,830		11,599,830
Common stock, shares outstanding				11,599,830		11,599,830
Preferred stock, share issued				0		0
Preferred stock, shares outstanding				0		0
In-kind Contribution of Service				$ 32,500	$ 32,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding				$ 19,288
C R G Finance A G [Member] | Warrant [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Issued		368,111	17,655
Exercise price		$ 0.225
Fair value		$ 34,405	$ 1,670
Volatility		45%	45%
Risk free interest rate		2.20%	2.51%
Expected life		5 years	5 years
Offering price			$ 0.225
Scientific Advisor [Member] | Warrant [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Issued	100,000
Exercise price	$ 0.90
Fair value	$ 1,905
Volatility	45%
Risk free interest rate	2.63%
Expected life	5 years
Offering price	$ 0.225
Vested				100,000		100,000

Stock Option Plan (Stock Option

Stock Option Plan (Stock Options Outstanding) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Options outstanding, beginning of period	100,000	100,000
Weighted average exercise price outstanding, beginning of period	$ 0.225	$ 0.225
Options outstanding, Granted
Weighted average exercise price, Granted
Options outstanding, Exercised
Weighted average exercise price, Exercised
Options outstanding, Forfeited
Weighted average exercise price, Forfeited
Options outstanding, Expired
Weighted average exercise price, Expired
Options outstanding, end of period	100,000	100,000
Weighted average exercise price outstanding, end of period	$ 0.225	$ 0.225
Options outstanding Exercisable, end of period	100,000	100,000
Weighted average exercise price, Exercisable end of period	$ 0.225	$ 0.225
Options available for grant	1,000,000	1,000,000

Stock Option Plan (Stock Opti_2

Stock Option Plan (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, upper	$ 0.225	$ 0.225
Number Outstanding	100,000	100,000
Remaining Average Contractual Life	5 years 8 months 4 days	5 years 11 months 4 days
Weighted Average Exercise Price	$ 0.225	$ 0.225
Number Exercisable	100,000	100,000
Exercisable Weighted Average Exercise Price	$ 0.225	$ 0.225

Stock Option Plan (Details Narr

Stock Option Plan (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Jun. 14, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Total awards reserved		1,100,000
Options issued
Exercise price
Intrinsic value		$ 43,500		$ 5,000
Chief Executive Officer [Member]
Defined Benefit Plan Disclosure [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45%
Risk free rate	2.20%
Expected term	10 years
Stock option expense		$ 0	$ 0